Aberdeen Group plc Has $52.83 Million Position in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Aberdeen Group cut its stake in Alnylam by 15.6%, selling 24,550 shares to hold 132,846 shares valued at about $52.83 million after the quarter.
• Company insiders have been sellers, offloading a total of 53,923 shares worth roughly $18.07 million in the last quarter, leaving insiders with about 1.50% ownership.
• Recent results missed expectations—Alnylam reported $1.25 EPS vs. $1.43 expected and $1.10B revenue vs. $1.16B, though revenue rose 84.9% year‑over‑year; analysts’ consensus is a “Moderate Buy” with an average target of $473.87.

Aberdeen Group plc lessened its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 15.6% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 132,846 shares of the biopharmaceutical company's stock after selling 24,550 shares during the period. Aberdeen Group plc owned 0.10% of Alnylam Pharmaceuticals worth $52,826,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also added to or reduced their stakes in ALNY. Root Financial Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the 3rd quarter worth about $25,000. Salomon & Ludwin LLC acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $27,000. Caitong International Asset Management Co. Ltd bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $29,000. Ameriflex Group Inc. bought a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at about $32,000. Finally, ORG Partners LLC lifted its position in Alnylam Pharmaceuticals by 70.2% during the third quarter. ORG Partners LLC now owns 80 shares of the biopharmaceutical company's stock worth $36,000 after acquiring an additional 33 shares during the last quarter. Institutional investors and hedge funds own 92.97% of the company's stock.

Insiders Place Their Bets

In other news, EVP Jeffrey V. Poulton sold 2,206 shares of the business's stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $722,795.90. Following the completion of the sale, the executive vice president directly owned 64,273 shares of the company's stock, valued at $21,059,048.45. The trade was a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Pushkal Garg sold 1,775 shares of the firm's stock in a transaction that occurred on Tuesday, March 3rd. The shares were sold at an average price of $319.74, for a total value of $567,538.50. Following the completion of the transaction, the executive vice president owned 23,406 shares in the company, valued at $7,483,834.44. This represents a 7.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 53,923 shares of company stock worth $18,072,087 in the last quarter. Insiders own 1.50% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $318.85 on Friday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The firm's fifty day moving average is $326.77 and its 200-day moving average is $395.64. The firm has a market cap of $42.29 billion, a P/E ratio of 186.46 and a beta of 0.39. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.71 and a current ratio of 2.76.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 EPS for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). The firm had revenue of $1.10 billion for the quarter, compared to the consensus estimate of $1.16 billion. Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business's revenue was up 84.9% compared to the same quarter last year. During the same period last year, the company posted ($0.65) EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Raymond James Financial restated an "outperform" rating and set a $472.00 price objective on shares of Alnylam Pharmaceuticals in a report on Monday, January 12th. Stifel Nicolaus lifted their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a "buy" rating in a report on Thursday, December 11th. Jefferies Financial Group restated a "hold" rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Wall Street Zen lowered Alnylam Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, March 21st. Finally, Chardan Capital reiterated a "buy" rating and set a $425.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, March 25th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and six have given a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $473.87.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.